This product is for research use only, not for human use. We do not sell to patients.
Size | Price | Stock |
---|---|---|
100mg | $675 | Check With Us |
200mg | $1000 | Check With Us |
500mg | $1600 | Check With Us |
Cat #: V32637 CAS #: 154229-21-7 Purity ≥ 99%
Description: D4-abiraterone is an active metabolite of abiraterone Δ4-Abiraterone (D4A) which is a CYP17A1 inhibitor and an androgen receptor antagonist (IC50 of 5.3 nM). Abiraterone (formerly CB-7598; Zytiga) is an approved anticancer medication acting as an irreversible and selective CYP17 inhibitor.
Publications Citing InvivoChem Products
Product Promise
- Physicochemical and Storage Information
- Protocol
- Related Biological Data
- Stock Solution Preparation
- Quality Control Documentation
Molecular Weight (MW) | 347.49 |
---|---|
Molecular Formula | C24H29NO |
CAS No. | 154229-21-7 |
SMILES Code | O=C1CC[C@@]2(C)C(CC[C@]3([H])[C@]2([H])CC[C@@]4(C)[C@@]3([H])CC=C4C5=CN=CC=C5)=C1 |
Synonyms | D4A; CB 7627; Δ4-Abiraterone; Abiraterone D4A metabolite; D4-abiraterone; |
Protocol | In Vitro | D4-abiraterone (D4A ) (10 mM) nearly completely blocks conversion from D4-androstenedione (AD) to 5α-androstanedione and other 5α-reduced androgens. The affinity of D4-abiraterone for mutant (expressed in LNCaP, half-maximum inhibitory concentration (IC50=5.3 nM)) and wild type (expressed in LAPC4, IC50=7.9 nM) androgen receptor (AR) is greater than that of abiraterone (Abi) (IC50=418 and >500 nM, respectively). Compare with Abi, D4-abiraterone clearly better suppresses PSA, TMPRSS2 and FKBP5 expression in LNCAP, LAPC4 and C4-2 cell lines. D4-abiraterone also inhibits AR target gene expression in a dose-dependent manner. |
---|---|---|
In Vivo | D4-abiraterone (D4A) is tenfold more potent than abiraterone (Abi) in blocking conversion from dehydroepiandrosterone (DHEA) by 3β-hydroxysteroid dehydrogenase (3βHSD) to D4-androstenedione (AD) in LNCaP and VCaP xenografts. 0.1 μM D4-abiraterone is equivalent to 1 μM Abi for blocking AD accumulation at 48 h in both LNCaP and VCaP xenografts. Progression is significantly delayed in the D4-abiraterone group compare with the Abi acetate group (P=0.011). D4-abiraterone treatment increases progression-free survival compare with Abi acetate. |
Solvent volume to be added | Mass (the weight of a compound) | |||
---|---|---|---|---|
Mother liquor concentration | 1mg | 5mg | 10mg | 20mg |
1mM | 2.8778 mL | 14.3889 mL | 28.7778 mL | 57.5556 mL |
5mM | 0.5756 mL | 2.8778 mL | 5.7556 mL | 11.5111 mL |
10mM | 0.2878 mL | 1.4389 mL | 2.8778 mL | 5.7556 mL |
20mM | 0.1439 mL | 0.7194 mL | 1.4389 mL | 2.8778 mL |
This equation is commonly abbreviated as: C1 V1 = C2 V2
- (1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
- (2) Be sure to add the solvent(s) in order.